Equities research analysts expect Illumina, Inc. (NASDAQ:ILMN) to announce $1.09 billion in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Illumina’s earnings, with the highest sales estimate coming in at $1.10 billion and the lowest estimate coming in at $1.09 billion. Illumina reported sales of $953.00 million during the same quarter last year, which indicates a positive year-over-year growth rate of 14.4%. The company is scheduled to announce its next earnings results on Thursday, February 10th.
According to Zacks, analysts expect that Illumina will report full year sales of $4.42 billion for the current financial year, with estimates ranging from $4.41 billion to $4.43 billion. For the next fiscal year, analysts anticipate that the business will report sales of $4.77 billion, with estimates ranging from $4.64 billion to $4.84 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Illumina.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, November 4th. The life sciences company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.24 by $0.21. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.04 billion. Illumina had a net margin of 21.17% and a return on equity of 15.03%. The business’s revenue was up 39.3% on a year-over-year basis. During the same period last year, the company posted $1.02 EPS.
ILMN traded down $0.18 on Friday, reaching $365.56. 1,112,567 shares of the company traded hands, compared to its average volume of 895,605. Illumina has a one year low of $301.73 and a one year high of $555.77. The firm has a fifty day simple moving average of $405.93 and a two-hundred day simple moving average of $439.86. The company has a market cap of $57.14 billion, a P/E ratio of 60.03, a price-to-earnings-growth ratio of 2.17 and a beta of 0.87. The company has a quick ratio of 2.24, a current ratio of 2.68 and a debt-to-equity ratio of 0.16.
In other Illumina news, SVP Susan H. Tousi sold 100 shares of the stock in a transaction dated Tuesday, September 28th. The shares were sold at an average price of $418.04, for a total transaction of $41,804.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Charles Dadswell sold 314 shares of the stock in a transaction dated Wednesday, September 22nd. The stock was sold at an average price of $436.69, for a total transaction of $137,120.66. The disclosure for this sale can be found here. Insiders have sold 14,507 shares of company stock valued at $6,001,240 over the last 90 days. 0.23% of the stock is currently owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the company. CHICAGO TRUST Co NA acquired a new stake in shares of Illumina during the second quarter worth about $1,086,000. Eukles Asset Management raised its holdings in Illumina by 6.9% in the second quarter. Eukles Asset Management now owns 4,892 shares of the life sciences company’s stock valued at $2,315,000 after acquiring an additional 315 shares in the last quarter. Premier Fund Managers Ltd acquired a new stake in Illumina in the second quarter valued at approximately $12,942,000. Rothschild Investment Corp IL raised its holdings in Illumina by 7.2% in the second quarter. Rothschild Investment Corp IL now owns 741 shares of the life sciences company’s stock valued at $351,000 after acquiring an additional 50 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its holdings in Illumina by 3.0% in the third quarter. Louisiana State Employees Retirement System now owns 17,200 shares of the life sciences company’s stock valued at $6,976,000 after acquiring an additional 500 shares in the last quarter. 88.24% of the stock is currently owned by institutional investors and hedge funds.
Illumina Company Profile
Illumina, Inc engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions.
Recommended Story: What are the advantages of the Stochastic Momentum Index?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.